Clincosm LogoSign in Get a demo

hepatocellular carcinoma

Showing 51 - 75 of 1,472
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Hepatocellular Carcinoma Trial in Hangzhou (Fruquintinib, Sintilimab, Transcatheter arterial chemoembolization(TACE))

Recruiting
  • Hepatocellular Carcinoma
  • Hangzhou, Zhejiang, China
    Guoliang Shao
Aug 1, 2023

Hepatocellular Carcinoma Trial in Villejuif (RAPID procedure)

Not yet recruiting
  • Hepatocellular Carcinoma
  • RAPID procedure
  • Villejuif, France
    AP-HP, Paul Brousse Hospital
Jul 24, 2023

Hepatocellular Carcinoma Trial (The neutrophil-to- lymphocyte ratio, Prognostic nutrition index)

Not yet recruiting
  • Hepatocellular Carcinoma
  • The neutrophil-to- lymphocyte ratio
  • Prognostic nutrition index
  • (no location specified)
Jul 28, 2023

Adebrelimab, Hepatocellular Carcinoma, Transformation Trial in Xiamen (TACE with adebrelimab and bevacizumab)

Not yet recruiting
  • Adebrelimab
  • +4 more
  • TACE with adebrelimab and bevacizumab
  • Xiamen, Fujian, China
    The First Affiliated Hospital of Xiamen University
Jul 25, 2023

Hepatocellular Carcinoma Trial in Beijing (iNKT Cells, PD-1, Regorafenib)

Not yet recruiting
  • Hepatocellular Carcinoma
  • iNKT Cells
  • +2 more
  • Beijing, Beijing, China
    Beijing Youan Hospital,Capital Medical University
Jul 24, 2023

Hepatocellular Carcinoma, Hepatocellular Carcinoma Non-resectable, Liver Cancer Trial (EYE90 Microspheres Treatment)

Not yet recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • EYE90 Microspheres Treatment
  • (no location specified)
Jul 12, 2023

Hepatocellular Carcinoma Trial in Guangzhou (Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC)

Recruiting
  • Hepatocellular Carcinoma
  • Lenvatinib, Tislelizumab Combined with RALOX Regimen HAIC
  • Guangzhou, Guangdong, China
    Guangdong Provincial People's Hospital
Jul 12, 2023

Cancer Patients' Diagnostic and Management: Set-up of Indicators

Recruiting
  • Hepatocellular Carcinoma
  • Peritoneal Carcinoma
  • COLLAT-COVID is an observational study based on retrospective data issued from patients medial files.
  • Pierre-Bénite, France
    Hopital Lyon sud, Hospices civils de Lyon
Jul 7, 2023

Hepatocellular Carcinoma Trial in Yerevan

Recruiting
  • Hepatocellular Carcinoma
    • Yerevan, Armenia
      Nikomed Medical Center
    Jun 28, 2023

    Hepatocellular Carcinoma Trial in Changsha (No interventions.)

    Recruiting
    • Hepatocellular Carcinoma
    • No interventions.
    • Changsha, Hunan, China
      Liangrong Shi
    Jun 27, 2023

    Hepatocellular Carcinoma Trial in Shanghai (CAR-GPC3 T cells)

    Recruiting
    • Hepatocellular Carcinoma
    • CAR-GPC3 T cells
    • Shanghai, China
      Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong Universi
    Jun 22, 2023

    Hepatocellular Carcinoma Trial in Shanghai (Cadonilimab+TACE)

    Active, not recruiting
    • Hepatocellular Carcinoma
    • Shanghai, Shanghai, China
      Eastern hepatobilliary surgery hospital
    Jun 21, 2023

    Hepatocellular Carcinoma, Lenvatinib, Tislelizumab Trial in Hangzhou (TACE, Tislelizumab, Lenvatinib)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • +5 more
    • TACE
    • Tislelizumab, Lenvatinib
    • Hangzhou, Zhejiang, China
      1# Banshan East Rd. Zhejiang cancer hospital
    Jun 17, 2023

    Pre-transplant ICI Exposure and Post-transplant Graft Rejection

    Recruiting
    • Graft Rejection
    • +3 more
    • Immune checkpoint inhibitor
    • Guangzhou, Guangdong, China
      Organ Transplantation Center, Sun Yat-sen Memorial Hospital, Sun
    Jun 21, 2023

    Hepatocellular Carcinoma, Recurrence, Immune Checkpoint Inhibitor Trial in Nanning (Adjuvant tislelizumab plus lenvatinib,

    Not yet recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • Adjuvant tislelizumab plus lenvatinib
    • Adjuvant tislelizumab
    • Nanning, China
      Jian-Hong Zhong
    Jun 11, 2023

    Hepatocellular Carcinoma Trial in Seoul (AtezoBev with combined radiotherapy)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • AtezoBev with combined radiotherapy
    • Seoul, Korea, Republic of
      Severance hospital
    Jun 9, 2023

    Hepatocellular Carcinoma Trial (TACE(transcatheter arterial chemoembolization), lenvatinib, Icaritin soft capsules)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • TACE（transcatheter arterial chemoembolization）
    • +2 more
    • (no location specified)
    Jun 5, 2023

    Hepatocellular Carcinoma Trial (Prednisone)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • (no location specified)
    Jun 2, 2023

    Hepatocellular Carcinoma Trial (Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Lenvatinib at a dose of 8 mg or 12 mg based on body weight + tislelizumab for one 21-day cycle
    • (no location specified)
    Jun 12, 2023

    Hepatocellular Carcinoma Trial (Cryoablation, Tislelizumab, Lenvatinib)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Cryoablation
    • +2 more
    • (no location specified)
    May 31, 2023

    Hepatocellular Carcinoma, Liver Function, Postoperative Complications Trial (Vitamin D, Placebo)

    Not yet recruiting
    • Hepatocellular Carcinoma
    • +2 more
    • Vitamin D
    • Placebo
    • (no location specified)
    Jun 4, 2023

    Hepatocellular Carcinoma Trial in Nanjing (hypovolemic phlebotomy)

    Recruiting
    • Hepatocellular Carcinoma
    • hypovolemic phlebotomy
    • Nanjing, Jiangsu, China
      The First Affiliated Hospital of Nanjing Medical University
    Jun 1, 2023

    Hepatocellular Carcinoma Trial in Guangzhou (Atezolizumab, Bevacizumab, HAIC with FOLFOX)

    Recruiting
    • Hepatocellular Carcinoma
    • Guangzhou, Guangdong, China
      Cancer Center Sun Yat-sen University
    May 24, 2023

    Hepatocellular Carcinoma Trial in Guangzhou (Candonilimab, Bevacizumab)

    Withdrawn
    • Hepatocellular Carcinoma
    • Guangzhou, Guangdong, China
      Cancer Center Sun Yat-sen University
    Jun 1, 2023

    Hepatocellular Carcinoma Trial in Guangzhou (Cadonilimab, transjugular intrahepatic portosystemic shunt (TIPS))

    Not yet recruiting
    • Hepatocellular Carcinoma
    • Cadonilimab
    • transjugular intrahepatic portosystemic shunt (TIPS)
    • Guangzhou, Guangdong, China
      Sun Yat-sen University Cancer Center
    May 30, 2023